1. Sharma, A.; Bhatt, N.S.; Martin, A.S.; Abid, M.B.; Bloomquist, J.; Chemaly, R.F.; Dandoy, C.; Gauthier, J.; Gowda, L.; Perales, M.-A.; et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study. Lancet Haematol. 2021, 8, e185–e193. [CrossRef]
2. Mittelman, M.; Magen, O.; Barda, N.; Dagan, N.; Oster, H.S.; Leader, A.; Balicer, R. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood 2022, 139, 1439–1451. [CrossRef] [PubMed]
3. Watanabe, M.; Yakushijin, K.; Funakoshi, Y.; Ohji, G.; Hojo, W.; Sakai, H.; Saeki, M.; Hirakawa, Y.; Matsumoto, S.; Sakai, R.; et al. The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation. Vaccines 2022, 10, 158. [CrossRef] [PubMed]
4. Ali, H.; Ngo, D.; Aribi, A.; Arslan, S.; Dadwal, S.; Marcucci, G.; Nakamura, R.; Forman, S.J.; Chen, J.; Al Malki, M.M. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplant. Cell. Ther. 2021, 27, 938.e1–938.e6. [CrossRef] [PubMed]
5. Hill, J.A. Humoral Immunity After mRNA SARS-CoV-2 Vaccination in Allogeneic HCT Recipients-Room for Improvement and Much to Learn. JAMA Netw. Open 2021, 4, e2127454. [CrossRef] [PubMed]
6. Ge, C.; Du, K.; Luo, M.; Shen, K.; Zhou, Y.; Guo, K.; Liu, Y.; Yin, C.; Li, Y.; Li, G.; et al. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: A systematic review and meta-analysis. Exp. Hematol. Oncol. 2022, 11, 46. [CrossRef] [PubMed]
7. Imai, K.; Kitagawa, Y.; Tabata, S.; Kubota, K.; Nagura-Ikeda, M.; Matsuoka, M.; Miyoshi, K.; Sakai, J.; Ishibashi, N.; Tarumoto, N.; et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J. Med. Virol. 2021, 93, 3211–3218. [CrossRef] [PubMed]
8. Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013, 48, 452–458. [CrossRef] [PubMed]
9. Ram, R.; Hagin, D.; Kikozashvilli, N.; Freund, T.; Amit, O.; Bar-On, Y.; Beyar-Katz, O.; Shefer, G.; Moshiashvili, M.M.; Karni, C.; et al. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. Transplant. Cell. Ther. 2021, 27, 788–794. [CrossRef] [PubMed]
10. Attolico, I.; Tarantini, F.; Carluccio, P.; Schifone, C.P.; Delia, M.; Gagliardi, V.P.; Perrone, T.; Gaudio, F.; Longo, C.; Giordano, A.; et al. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. Br. J. Haematol. 2021, 196, 928. [CrossRef] [PubMed]
11. Canti, L.; Humblet-Baron, S.; Desombere, I.; Neumann, J.; Pannus, P.; Heyndrickx, L.; Henry, A.; Servais, S.; Willems, E.; Ehx, G.; et al. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. J. Hematol. Oncol. 2021, 14, 174. [CrossRef] [PubMed]
12. Kimura, M.; Ferreira, V.H.; Kothari, S.; Pasic, I.; Mattsson, J.I.; Kulasingam, V.; Humar, A.; Mah, A.; Delisle, J.-S.; Ierullo, M.; et al. Safety and Immunogenicity after A Three-dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. Transplant. Cell. Ther. 2022, 28, 706.e1–706.e10. [CrossRef] [PubMed]
13. Bonnet, B.; Chabrolles, H.; Archimbaud, C.; Brebion, A.; Cosme, J.; Dutheil, F.; Lambert, C.; Junda, M.; Mirand, A.; Ollier, A.; et al. Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. Front. Immunol. 2022, 13, 842912. [CrossRef] [PubMed]
14. Wu, X.; Wang, L.; Shen, L.; He, L.; Tang, K. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients. J. Hematol. Oncol. 2022, 15, 81. [CrossRef] [PubMed]
15. Redjoul, R.; Le Bouter, A.; Parinet, V.; Fourati, S.; Maury, S. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. Lancet Haematol. 2021, 8, e681–e683. [CrossRef]
16. Maillard, A.; Redjoul, R.; Klemencie, M.; Labussière, H.; Le Bourgeois, A.; D’Aveni, M.; Berceanu, A.; Chantepie, S.; Botella, C.; Loschi, M.; et al. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood 2022, 139, 134–137. [CrossRef] [PubMed]